KELUN PHARMA(SZ:002422) Xin Lang Cai Jing·2025-10-17 01:33Core Insights - On October 16, 2023, Kelun Pharmaceutical's stock increased by 0.23%, with a trading volume of 348 million yuan. The company experienced a net financing outflow of 11.58 million yuan on that day [1] - As of June 30, 2025, Kelun Pharmaceutical reported a revenue of 9.083 billion yuan, a year-on-year decrease of 23.20%, and a net profit attributable to shareholders of 1.001 billion yuan, down 44.41% year-on-year [2] - The company has distributed a total of 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [2] Financing and Margin Trading - On October 16, 2023, Kelun Pharmaceutical had a financing buy-in of 24.09 million yuan, with a total financing balance of 9.56 billion yuan, representing 1.72% of its market capitalization [1] - The company's margin trading balance is above the 70th percentile of the past year, indicating a relatively high level of financing activity [1] - The short selling activity on the same day included a repayment of 15,300 shares and a short sale of 4,400 shares, with a total short selling amount of 153,500 yuan [1] Shareholder Structure - As of June 30, 2025, Kelun Pharmaceutical had 34,200 shareholders, an increase of 2.55% from the previous period, with an average of 38,138 circulating shares per shareholder, a decrease of 2.49% [2][3] - The top three circulating shareholders include China Europe Medical Health Mixed A, holding 42.60 million shares, and Hong Kong Central Clearing Limited, holding 39.99 million shares, with the latter reducing its holdings by 2.71 million shares [3]